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ABSTRACT
Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 
1 (PD-L1) have gained massive attention in cancer research due to recent availability 
and their targeted antitumor effects. Their role in prostate cancer is still undetermined. 
We constructed tissue microarrays from prostatectomy specimens from 535 prostate 
cancer patients. Following validation of antibodies, immunohistochemistry was used to 
evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells 
of primary tumors. PD-L1 expression was commonly seen in tumor epithelial cells (92% 
of cases). Univariate survival analysis revealed a positive association between a high 
density of PD-1+ lymphocytes and worse clinical failure-free survival, limited to a trend 
(p = 0.084). In subgroups known to indicate unfavorable prostate cancer prognosis 
(Gleason grade 9, age < 65, preoperative PSA > 10, pT3) patients with high density 
of PD-1+ lymphocytes had a significantly higher risk of clinical failure (p = < 0.001, 
p = 0.025, p = 0.039 and p = 0.011, respectively). In the multivariate analysis, high 
density of PD-1+ lymphocytes was a significant negative independent prognostic factor 
for clinical failure-free survival (HR = 2.48, CI 95% 1.12–5.48, p = 0.025).
INTRODUCTION
Prostate cancer is a major contributor to cancer 
burden and death among men worldwide [1, 2], and issues 
multiple challenges regarding diagnostics and disease 
management. There is a lack of molecular markers 
suitable for determining the prognosis and thus intensity 
of treatment, resulting in overtreatment with unnecessary 
side effects on the one hand and undertreatment and 
disease progression on the other [3]. Once a patient 
reaches a state of metastatic castration-resistant disease, 
no curative treatment options are available. Hence, there 
is an urgent need for new prognostic markers, as well as 
better treatment options, for both confined and widespread 
disease in prostate cancer.
It has become evident that for a cancerous tumor to 
develop and metastasize it has to escape anti-tumor immune 
response, especially CD8+ cytotoxic T cell mediated 
elimination [4]. Multiple mechanisms have been identified, 
including the exploitation of natural immunosuppressive 
pathways such as the programmed cell death protein 1 
(PD-1) pathway [5, 6]. In healthy individuals, this pathway 
is important for maintaining self-tolerance, as well as 
curbing T cells during an immune response, preventing 
collateral damage to healthy tissues [7]. The pathway 
consists of the receptor programmed cell death protein 1 
(known as PD-1 or CD279) and its ligands programmed 
death ligand 1 (known as PD-L1, CD274 or B7-H1) 
and programmed death ligand 2 (known as PD-L2, B7-
DC or CD273), where the former is believed to be of 
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greatest significance. PD-1 can primarily be found on 
T cells, but also B cells, Natural Killer T (NKT) cells, 
activated monocytes, and dendritic cells (DCs) [7]. PD-L1 
is typically found on antigen-presenting cells such as 
macrophages, but can be found on a wide range of cells, 
including human cancer cells [5, 6]. It is proposed that 
malignant cells express PD-L1 through genetic mutations 
or epigenetic changes, and as a response to an inflammatory 
environment [5]. This enables them to directly inactivate 
tumor infiltrating lymphocytes (TILs), and hence escaping 
immune destruction. In addition to activating PD-1, PD-L1 
also has immunomodulatory effects within the cell on 
which it is expressed [5]. 
Knowledge about the PD-1 pathway’s 
immunosuppressive effects lead to the notion that its 
inhibition could restore T cell mediated immunity towards 
tumor cells [8]. Currently, drugs that target PD-1 have been 
approved by the US Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) for malignant 
melanoma and non-small cell lung cancer (NSCLC), 
and there are currently ongoing trials for drugs targeting 
PD-L1 [9, 10]. Disappointingly, three recent trials, 
including a total of 27 patients with metastatic castration-
resistant prostate cancer (mCRPC) receiving the PD-1 
inhibitor drug nivolumab, demonstrated no clinical benefit 
[11–13]. In light of the use and development of new PD-1 
pathway inhibitors, it is vital to gather information that can 
shed light on the expression of these immune checkpoint 
molecules in prostate cancer, and whether their expression 
is associated with prostate cancer survival. This might aid 
patient treatment decision-making as well as contributing 
to future research in PD-1 pathway directed therapies in 
prostate cancer patients.
Herein, we aimed to examine the potential 
prognostic significance of PD-1 and/or PD-L1 expression 
in prostate cancer. Consequently, we investigated 535 
primary prostate cancer tumors for expression of PD-L1 
in stromal and epithelial cells, as well as the expression of 
PD-1 and co-expression of PD-1 and CD8 in lymphocytes, 
and their associations with biochemical and clinical 
failure-free survival.
RESULTS
Patient characteristics and clinicopathological 
data 
Detailed clinical and histopathological 
characteristics are presented in Table 1. Median age at 
surgery was 62 (range 47–75). The prostatectomies were 
retropubic in 435 cases and perineal in 100 cases. At 
the last follow-up in December 2015, 200 patients had 
experienced BF, 56 patients had CF, and 18 patients were 
dead of prostate cancer. Elaborate information on the 
cohort has been previously published [14].
Programmed cell death protein 1 and programmed 
death ligand 1 expression in prostate tumor tissue
Of the total cohort of 535 patients, 
immunohistochemistry (IHC) tumor scoring was 
possible for 402 cases for PD-L1, and 396 for PD-1. 
PD-L1 expression (Figure 1) was both cytoplasmatic 
and membranous. Intraluminal secretions and some 
intracellular granules seemed to stain intensively and were 
disregarded as artifacts. PD-L1 staining in tumor epithelial 
(TE) cells was positive in 371/402 (92%) cases, and 
236/402 (59%) cases had a high PD-L1 intensity score. In 
addition, 267/402 (66%) of patients had PD-L1+ stromal 
cells. In general, PD-1+ cells were sparse (Figure 1) and fit 
the morphology of lymphocytes. In total, 156/396 (39%) 
cases had such intratumoral PD-1+ lymphocytes, and 
43/396 (11%) cases had a high density. In addition, we 
observed few intraepithelial PD-1+ cells. Some of these 
resembled tumor cells, as recently described for malignant 
melanoma [15]. Unfortunately, we were not certain these 
were tumor cells using only morphological assessment, and 
this, in addition to low numbers, made them impossible to 
quantify by scoring. CD8 and PD-1 double staining showed 
co-expression of CD8 and PD-1, but also lymphocytes 
with single expression of one marker (Figure 1). However, 
the brown CD8 staining overpowered the red stain of 
PD-1, making quantification by scoring difficult.
Correlations between programmed cell death 
protein 1, programmed death ligand 1, lymphocyte 
markers and clinicopathological variables
The expression of PD-L1+ tumor stromal (TS) cells 
correlated significantly with PD-L1+ TE cells (r = 0.36, 
p = < 0.001), and had a weak correlation with intratumoral 
PD-1+ lymphocytes (r = 0.21, p = < 0.001). The 
expression of PD-L1 in TE cells and TS cells, in addition 
to intratumoral PD-1+ lymphocytes did not correlate to 
previously published [16] tumor tissue expression of 
lymphocyte markers CD3, CD4, CD8 and CD20. The 
expression of PD-1+ lymphocytes and PD-L1 in TS and 
TE was not correlated to clinicopathological variables 
(age, pT stage, preoperative PSA, Gleason grade, tumor 
size, perineural infiltration, lymphovascular infiltration 
and non-apical positive surgical margin).
Univariate survival analysis
The results of the univariate survival analyses are 
presented in Table 1 and Figures 2 and 3. Neither PD-
L1+ TE cells nor PD-L1+ TS cells reached statistical 
significance for predicting biochemical failure (BF) 
or clinical failure (CF), but there was a trend towards a 
negative association between PD-L1 expression in TE 
cells and outcome, most prominently for biochemical 
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failure-free survival (BFFS) (HR: 1.34 (CI95% 
0.97–1.85) p = 0.078, Table 1, Figure 2). With regard to 
PD-1+ lymphocytes, there was a trend for worse clinical 
failure-free survival (CFFS) in the entire patient material 
(HR: 1.96 (CI95% 0.90–4.25), p = 0.084, Table 1, 
Figure 3), but subgroups known to indicate unfavorable 
prostate cancer prognosis had a significantly higher risk 
for CF if they had a high density of intratumoral PD-1+ 
lymphocytes: age < 65 (p = 0.025), pT3 stage (p = 0.011), 
preoperative PSA > 10 (p = 0.039), and Gleason grade 9 
(p = < 0.001) (Figure 3). 
Multivariate survival analysis 
Clinicopathological variables and PD-1 and 
PD-L1 variables with p < 0.10 from the univariate 
analyses (Table 1) were entered into three different 
multivariate models and results are presented in Table 2. 
High expression of intratumoral PD-1+ lymphocytes was 
a significant negative independent prognostic factor for 
CFFS (HR = 2.48, CI95% 1.12–5.48), p = 0.025) together 
with Gleason grade and perineural infiltration. 
DISCUSSION
In our large, multicenter cohort of 535 prostate cancer 
cases, we observed a high density of PD-1+ lymphocytes 
in prostate cancer tumor tissue to independently predict 
shorter CFFS. The prognostic impact of PD-1 was stronger 
than for any of the renowned clinicopathological features, 
except for Gleason grade. In addition, a high density of 
PD-1+ lymphocytes was significantly associated with 
shorter CFFS in most subgroups related to worse prostate 
cancer prognosis, such as low age, high pT-stage, high 
preoperative PSA, and high Gleason grade. Furthermore, 
92% of the cases had some level of PD-L1 expression in 
TE cells, but no significant association between the marker 
and outcome was observed. 
Figure 1: Immunohistochemical analysis. (A) Low density PD-L1+ stromal cells, (B) High density PD-L1+ stromal cells, (C) Low 
intensity PD-L1+ tumor epithelial cells, (D) High intensity PD-L1+ tumor epithelial cells, (E) Negative isotype control antibody for PD-L1 
(prostate TMA), (F) Negative control for PD-L1 (brain), (G) Positive control for PD-L1 (placenta), (H) Low density of intratumoral PD-
1+ lymphocytes, (I) High density of intratumoral PD-1+ lymphocytes, (J) PD-1 and CD8 double stain with pink showing PD-1 positivity, 
and brown showing CD8 positivity, (K) Negative isotype control antibody for PD-1, (L) Negative control for PD-1 (brain), (M) Positive 
control for PD-1 (tonsil), (N) Positive control for PD-1 and CD8 double stain (tonsil). Magnification ×400 for all, except (N) which shows 
×50 magnification.
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Table 1: Patient characteristics, clinicopathological variables, and molecular markers as predictors 
of biochemical- and clinical failure in prostate cancer patients (n = 535), (univariate analysis; log-
rank test) significant P values in bold (threshold ≤ 0.05)
Variable Patients BF CF
(n) (200 events) (56 events)
5-year EFS (%) p 10-year EFS (%) p
Age 0.237 0.038
≤ 65 years 357 77 94
> 65 years 178 70 91
pT-stage < 0.001 < 0.001
pT2 374 83 97
pT3a 114 61 87
pT3b 47 43 74
Preop PSA < 0.001 0.029
PSA<10 308 81 95
PSA>10 221 68 89
Missing 6 - -
Gleason grade < 0.001 < 0.001
3+3 / Grade group 1 183 83 98
3+4 / Grade group 2 219 77 94
4+3 / Grade group 3 81 70 90
4+4 / Grade group 4 17 58 86
>8 / Grade group 5 35 37 65
Tumor Size < 0.001 0.002
0-20 mm 250 83 96
>20 mm 285 68 90
PNI < 0.001 < 0.001
No 401 80 96
Yes 134 60 83
PSM 0.049 0.198
No 249 69 90
Yes 286 81 96
Non-apical PSM < 0.001 < 0.001
No 381 82 96
Yes 154 57 85
Apical PSM 0.063 0.427
No 325 74 92
Yes 210 77 93
LVI < 0.001 < 0.001
No 492 77 95
Yes 43 47 69
Surgical proc 0.466 0.308
Retropubic 435 77 92
Perineal 100 68 95
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To our knowledge, this is the first study to examine 
the prognostic impact of both PD-1 and its ligand PD-L1 
in the same prostate cancer cohort, and the first to explore 
prognostic effects of PD-1+ lymphocytes in prostate cancer 
altogether. In addition to novelty, two major strengths 
in our study are the large, unselected patient population 
and the long follow-up time enabling us to calculate 
prognoses with regard to relevant clinical endpoints. 
Since no antibody for quantifying PD-1, and especially 
PD-L1, in formalin-fixed paraffin embedded (FFPE) tissue 
is uniformly accepted as standard, the antibodies used 
herein underwent stringent confirmatory validation in 
our laboratory, in addition to the manufacturers in-house 
validation.
PD-1+ lymphocytes in TS 0.489 0.084
Low 353 74 94
High 43 69 87
Missing 139
PD-L1+ TS cells 0.899 0.680
Low 245 28 92
High 157 74 91
Missing 133
PD-L1+ TE cells 0.078 0.603
Low 166 77 92
High 236 71 92
Missing 133
Abbreviations: BF = biochemical failure; CF = clinical failure; EFS = event free survival in months; LVI = lymphovascular 
infiltration; p = p value for difference in event free survival with log rank analysis; PD-1 = programmed cell death protein 1; 
PD-L1 = programmed death-ligand 1; PNI = Perineural infiltration; Preop = preoperative; PSA = Prostate specific antigen; 
PSM = Positive surgical margin; pT-stage = pathological tumor stage; Proc = procedure; TE = tumor epithelial cells; TS = 
tumor stromal cells 
Figure 2: Biochemical failure-free survival curves for PD-L1 intensity in tumor epithelial cells. Grey lines indicate low 
intensity, whereas black lines indicate high intensity.
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Table 2: Independent predictors for biochemical- and clinical failure in prostate cancer patients 
(n = 535), (cox regression analysis, backward conditional model)
Variable Model 1 (clinicopathological) Model 2 (PD-L1+ TE) Model 3 (PD-1+ lymphocytes in TS)
BF CF BF CF
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age NE NS NE NS
≤ 65 years
 > 65 years
pT-stage 0.001 NS 0.003 NS
pT2 1.00 1.00
pT3a 1.48 (1.02–2.14) 0.040 1.50 (1.00–2.27) 0.050
pT3b 2.34 (1.47–3.74) < 0.001 2.41 (1.45–4.00) 0.001
Preop PSA 0.033 NS NS NS
PSA < 10 1.00
PSA > 10 1.37 (1.03–1.84)
Gleason grade 0.040 < 0.001 0.011 < 0.001
3 + 3/Grade group 1 1.00 1.00 1.00 1.00
3 + 4/Grade group 2 1.24 (0.86–1.78) 0.249 3.74 (1.40–9.98) 0.009 1.02 (0.67–1.56) 0.920 4,70 (1,31–16,81) 0.017
4 + 3/Grade group 3 1.73 (1.12–2.68) 0.013 5.08 (1.73–14.88) 0.003 1.98 (1.21–3.25) 0.007 6,26 (1,66–23,63) 0.007
4 + 4/Grade group 4 2.13 (1.06–4.31) 0.035 5.95 (1.41–25.14) 0.015 2.05 (0.96–4.37) 0.063 10,10 (2,04–50,17) 0.005
> 8/Grade group 5 1.92 (1.09–3.39) 0.025 13.09 (4.46–38.40) 0.000 1.83 (1.00–3.36) 0.050 20,34 (5,71–72,48) < 0.001
Tumor size NS NS NS NS
0–20 mm
> 20 mm
PNI 0.045 NS 0.017 0,012
No 1.00 1.00 1.00
Yes 1.40 (1.01–1.94) 1.56 (1.08–2.25) 2,32 (1,21–4,47)
Non-apical PSM 0.001 NS 0.026 NS
No 1.00 1.00
Yes 1.73 (1.25–2.38) 1.50 (1.05–2.14)
Apical PSM 0.026 NE NS NE
No 1.00
Yes 0.71 (0.52–0.96)
LVI NS NS NS NS
No 
Yes




lymphocytes in TS NE NE NE 0.025
Low 1.00
High 2.48 (1.12–5.48)
Abbreviations: BF = biochemical failure; CF = clinical failure; CI = confidence interval; HR = hazard ratio; LVI = lymphovascular infiltration; NE = not entered in analysis; 
NS = not significant; p = p value for difference in survival with Cox regression analysis; PD-1 = programmed cell death protein 1; PD-L1 = programmed death-ligand 1; PNI = 
Perineural infiltration; Preop = preoperative; PSA = Prostate specific antigen; PSM = Positive surgical margin; pT-stage = pathological tumor stage; TE = tumor epithelial cells; 
TS = tumor stromal cells 
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This study was conducted as a further elaboration 
of our previous observation that CD8+ lymphocytes are 
independent negative prognostic markers in prostate 
cancer [16]. Based on this discovery, we proposed that the 
detected CD8+ lymphocytes were indeed tumor-specific 
CD8+ T cells summoned to particularly aggressive tumors, 
but lacking functionality due to immunosuppression, 
for example due to activation of the PD-1 pathway. The 
CD8-marker represents a broad population of T cells with 
various roles, which might weaken its prognostic impact. 
A recent study in melanoma patients concluded that PD-1 
expression on CD8+ T cells identifies the subpopulation of 
tumor-specific effector cells [17] and hence, PD-1 may be 
a more specific prognostic marker than CD8. Surprisingly, 
our previously published lymphocyte marker expressions 
(CD3, CD4, CD8 and CD20) [16] did not correlate with 
PD-1 expression. To further explore the relationship 
between CD8+ and PD-1+ cells, we double-stained for 
both markers. By microscopic examination we detected 
co-expression of CD8 and PD-1 on lymphocytes as 
suspected, but also cells with single PD-1 or CD8 marker 
expression. Another explanation for lack of statistical 
correlations may be the different scoring methods of 
lymphocyte markers and PD-1 [16]. Also limiting the 
ability for comparison, the current study was performed on 
TMA cores cut from a much deeper tissue level than the 
lymphocyte study [16] hampering the ability to correlate 
these markers in the same tissue areas.
So far, translational studies regarding the prognostic 
impact of PD-1 and PD-L1 in human prostate cancer 
are sparse. For PD-1, only descriptive analyses have 
been published, all reporting PD-1+ lymphocytes to be 
present in prostate cancer carcinoma regions and/or in 
adjacent TLS [18–20].  With regard to PD-L1 positive 
tumor epithelial cells, descriptive analyses have been 
conflicting: Some research groups have reported lack 
of tumor epithelial positivity [12, 13, 20], while others 
have observed sparse expression [21] or cases with 
high expressions [18]. In a recent study, Gevensleben 
et al. found a high PD-L1 expression in TE cells to be 
an independent negative prognostic factor of BFFS in a 
cohort of 902 men with prostate cancer [22]. We could 
not fully reproduce this result, but in both univariate and 
multivariate analyses there was a consistent tendency of 
high expression of PD-L1 in TE cells in patients with a 
worse BFFS. In a larger study population, this association 
may have reached statistical significance.
There may be multiple possible biological 
explanations as to why we and others [18, 22] observe 
such high expression levels of PD-L1 in prostate tumor 
Figure 3: Clinical failure-free survival curves for PD-1+ lymphocytes in tumor stromal areas. Grey lines indicate low 
density, whereas black lines indicate high density. (A) All patients, (B) Patients with age < 65, (C) Patients with pTstage = 3, (D) Patients 
with preoperative PSA > 10, (E) Patients with Gleason grade = 9.
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epithelial cells. The most well-known mechanism of 
PD-L1 induction on tumor epithelial cells is cytokines 
such as IFNγ produced by adaptive immune cells in the 
tumor microenvironment (‘adaptive immune resistance’) 
[21, 23, 24]. However, we find that PD-L1 expression 
do not correlate to adaptive immune cell markers, which 
may suggest there is another mechanism at play. Several 
studies in different cancers have demonstrated that intrinsic 
oncogenic pathways may induce PD-L1 expression (‘innate 
immune resistance’). Some examples include EGFR 
mutations [25, 26] and loss of phosphatase and tensin 
homolog (PTEN) [27, 28]. To our knowledge, no such 
relationships have been found between intrinsic pathways 
and PD-L1 expression in human prostate cancer [21]. 
Our finding that an augmentation of the PD-1 
pathway leads to a worse prostate cancer prognosis 
may indicate that tumor immune escape, and thus tumor 
immune elimination, are important mechanisms in prostate 
cancer. CD8+ cytotoxic T cells are proposed to be one 
of the most important protagonists in tumor immune 
elimination, and the mechanisms by which tumor cells 
avoid attack by tumor-specific CD8+ T cells are crucial 
parts of the immune escape process [4]. Different escape 
routes have been proposed. FOXP3+CD25+CD4+ Tregs 
are known suppressors of CD8+ cytotoxic T cells, and are 
observed up-regulated in multiple cancer types, including 
prostate cancer [29–31]. In addition, the process of 
antigen presentation is often impaired in tumors, leading 
to inadequate activation and boosting of T cells [32]. 
Moreover, tumor-specific CD8+ T cells have been found 
to express exhaustion markers such as PD-1 and T-cell 
immunoglobulin and mucin-domain containing-3 (Tim-3) 
indicating that their presence not necessarily implies an 
effective ongoing immune elimination process [33–35]. 
Contributing to this, different tumor cells have been found 
to express molecules such as indoleamine-2,3-dioxygenase 
(IDO) [36] and PD-L1, known to impair function of CD8+ 
cytotoxic T cells [5].
There have been recent breakthroughs in PD-1 
pathway inhibition in other cancer diseases [9]. Our 
study has found the pathway molecules to be present in 
prostate cancer, and their presence to be associated to 
poor prognosis and as such, proposing them as attractive 
targets for inhibition. However, results from prostate 
cancer studies have so far proven mostly disappointing. 
At the time we conducted this study there had been 
published results from three different clinical trials with a 
total of 27 prostate cancer patients treated with the PD-1 
inhibitor nivolumab [11–13]. Unfortunately, no clinical 
benefits were observed for these cases, which may have 
several possible explanations. For an immune checkpoint 
inhibitor to be effective in cancer treatment, the cancer 
in question must be able to evoke an immune response. 
Thus, one possible reason why PD-1 blockage does not 
appear to work in prostate cancer, may be that it is not 
an immunogenic cancer type. However, there are several 
aspects contradicting this proposition. Firstly, prostate 
cancer can express multiple tumor-associated antigens 
necessary in triggering anti-tumor immune response 
[such as prostate-specific antigen (PSA), prostatic acid 
phosphatase (PAP), prostate-specific membrane antigen 
(PSMA), and prostate stem cell antigen (PSCA)] [37, 38]. 
Secondly, the FDA approved autologous dendritic cell-
based vaccine Sipuleucel-T extends survival in patients 
with mCRPC. Though its exact mechanisms are not 
known, the most likely explanation is that it generates a 
tumor-specific T cell mediated immune response [31]. 
Furthermore, the mechanisms by which anti-androgen 
treatment increases survival in prostate cancer are believed 
to be partly explained by its ability to boost a tumor 
specific immune response [38, 40–41]. 
A likely reason why nivolumab-trials have 
failed to show effect in prostate cancer patients may be 
differences in patient and tumor characteristics. Patients 
in both our and Gevensleben et al. [22] cohorts were 
hormone naïve while the mentioned nivolumab trials 
[11–13] only included patients with mCRPC. Hence, 
immunosuppression through the PD-1 pathway may be a 
less efficient mechanism in late stage, widespread cancer 
disease, and/or there may be a more direct relationship 
between androgens and the PD-1 pathway. In addition, all 
prostate cancer patients included in the nivolumab-studies 
was reported to be negative for tumor expression of PD-L1 
(< 5% PD-L1 positive cells) [12, 13]. As no prostate cancer 
patients with a high degree of PD-L1 positive tumor cells 
have received nivolumab, the trials give no genuine data on 
the efficacy of PD-1 pathway inhibitor treatment. However, 
we have, corroborating others [22], demonstrated that such 
expression is common in primary prostate cancer tumors 
from patients with localized disease. Though there is an 
ongoing debate regarding whether PD-L1 tumor expression 
can predict treatment effect, there are multiple indications 
that PD-L1 positivity enrich for response to PD-1 pathway 
inhibitors [43]. Hence, PD-1 pathway inhibitors should not 
be completely disregarded as ineffective in prostate cancer 
treatment, and in a recent trial with pembrolizumab 3/10 
patients had an almost complete PSA regression [44]. 
To conclude, we find PD-1+ lymphocytes in prostate 
cancer tumors to be an independent negative prognostic 
marker in post-prostatectomy hormone naïve patients. 
In addition, our observations imply that PD-1 pathway 
inhibitors may yield therapeutic benefit in selected groups 
of prostate cancer patients.
MATERIALS AND METHODS
Patient characteristics and clinicopathological 
data 
Six hundred and seventy-one patients who 
underwent radical prostatectomy as initial treatment 
for prostate adenocarcinoma from 1995 to 2005 were 
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retrospectively identified from the Departments of 
Pathology at the University Hospital of Northern Norway 
(n = 267), Nordland Hospital (n = 63), St. Olavs Hospital 
(n = 330), and Levanger Hospital (n = 11). One hundred 
and thirty-six patients did not meet the inclusion criteria 
due to: (i) radiotherapy to the pelvic region prior to 
surgery (n = 1), (ii) other malignancies within 5 years 
prior to the prostate cancer diagnosis (n = 4), (iii) 
inadequate paraffin-embedded tissue blocks (n = 130), 
and (iv) lack of follow-up data (n = 1). Thus, a total 
of 535 patients were included in this study. Complete 
demographic and clinical data were obtained from 
medical records. Two experienced pathologists (ER and 
LTB) reviewed all cases and registered histopathological 
data. Tumors were histologically classified according to 
WHO guidelines [45], graded in accordance with both the 
modified Gleason grading system [46, 47] and the new 
contemporary Gleason grading system [48], and staged 
in agreement with International Union Against Cancer 
(UICC) guidelines [49]. All demographic-, clinical- 
and histopathological data (Table 1) were registered in 
a SPSS data file and patients were de-identified. This 
report includes follow-up data as of December 2015. 
Median follow-up of survivors was 150 (range 17–245) 
months. For extensive information regarding our cohort, 
see our previous report [14]. The ethics of this study has 
been approved by The Regional Committees for Medical 
and Health Research Ethics (Protocol ID: 2009/1393, 
extended approval 2015), The Norwegian Data Protection 
Authority, and The Data Protection Official for Research 
(The Norwegian Social Science Data Service). Informed 
consent was not obtained, but the data was analyzed de-
identified and this report contains no identifiable details. 
Tissue microarray construction 
For each case, a pathologist (ER) histologically 
identified and marked separate areas of the most 
representative TE tissue, adjacent TS tissue, normal 
epithelial (NE) tissue, and normal stromal (NS) tissue. In 
brief, a tissue-arraying instrument (Beecher Instruments, 
Silver Springs, MD) with a 0.6 mm diameter needle was 
used to harvest a total of 6 cores from each case from 
the corresponding paraffin-embedded tissue blocks. The 
samples were inserted into a recipient paraffin block, and 
from each block 4 µm sections were cut with a Micron 
microtome (HM355S), affixed to glass slides, and sealed 
with paraffin. 
Validation of antibody specificity 
The primary antibodies used in this study were 
as follows: (i) PD-L1 rabbit monoclonal antibody 
(Cat#13684, clone: E1L3N, Cell Signaling Technology, 
Danvers, MA, USA), (ii) PD-1 mouse monoclonal 
antibody (Cat#ab52587, clone: NAT105, Abcam, 
Cambridge, UK) and (iii) CD8 rabbit monoclonal antibody 
(clone SP57; Ventana; Cat#790-4460). All applied 
antibodies had been subjected to in-house validation by 
their manufacturer. In addition, we performed confirmatory 
validation for PD-L1 and PD-1 to further accredit antibody 
specificity. Overexpressed human HEK293T cell lysates 
were utilized from OriGene for PD-L1 (#LY415473), 
PD-1 (#LY401555) and HEK293 as empty vector 
(#LY500001/negative control). Cells were incubated with 
2xSDS sample buffer (OriGene) for 10 minutes at 100°C. 
Equal amounts of protein lysates were resolved on to a 
4 to 12% Bis-Tris gel (Cat#NP0322; Life Technologies), 
and transferred onto an Odyssey nitrocellulose membrane 
(Cat#926-31092, LI-COR). The membrane was 
subsequently blocked for 1 hour at room temperature 
using Odyssey blocking buffer (Cat#927-40000, LI-COR). 
For PD-L1 1/1000, and for PD-1 1/50 dilution of primary 
antibody was applied and the membrane incubated 
overnight at 4˚C. PD-L1 (Cat#926-32213, LI-COR), and 
PD-1 (Cat#926-32212, LI-COR) RDye 800CW secondary 
antibodies with 1:1000 dilution was then applied, and the 
membrane incubated 1 hour at room temperature. Between 
antibody incubations, the membrane was washed 3 times 
for 5 minutes, each time in tris-buffered saline containing 
0.05% Tween 20 (Cat#T9039, Sigma-Aldrich). Molecular 
weight markers used were the MagicMark XP Western 
Protein Standard (Cat#LC5603, Invitrogen) and SeeBlue 
Plus2 Pre-stained Standard (Cat#LC5925, Invitrogen). The 
most prominent bands (Supplementary Figure 1) represent 
the observed molecular weight of the detected protein, 
which correspond intimately with the predicted weight. 
Rabbit anti-actin, diluted 1:1000 (Cat#A2066, Sigma-
Aldrich) was used as internal control and all lanes showed 
42 KDa molecular weight protein load as predicted 
(Supplementary Figure 1).
Immunohistochemistry
Prior to IHC analysis, all slides were heated at 
60°C for tissue fixation. PD-L1 IHC was performed on 
a Discovery-Ultra immunostainer (Ventana Medical 
Systems, Tucson, AZ). Slides were deparaffinized on-
board in three 8-minute cycles.  Antigen retrieval was 
done by using the EDTA-based solution (pH 8.0–8.5) 
CC1 reagent (Cat#950-124) at 95°C and incubating for 
64 minutes. Endogenous peroxidase was blocked by 
incubating with Discovery inhibitor (Cat#760-4840) for 
8 minutes. Primary antibody PD-L1 with 1/25 dilution was 
added and slides were incubated for 32 minutes at 37°C. 
Secondary antibody used was UltraMap anti-rabbit HRP 
(Cat#760-4315) incubating for 20 minutes, followed by 
8 minutes HRP amplification. Finally, ChromoMap DAB 
(Cat#760-159) was used to visualize the antigens. 
PD1/CD8 dual and PD1 IHC were performed using 
the Ventana Benchmark XT automated immunostainer 
(Ventana Medical Systems, Tucson, AZ). Antigen retrieval 
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was done for 30 minutes at approximately 100°C with CC1 
reagent (Cat#950-124). Primary CD8 prediluted antibody 
was incubated for 12 minutes and visualized using the 
polymer-based Ventana ultraView DAB detection kit 
(Cat#760-500). The protocol followed by an ultraWash 
step to wash off excess antibody. Antibody denaturation 
for 4 minutes at 90°C was performed to ensure that the 
first primary antibody was completely inactivated before 
applying the second primary antibody. The PD-1 primary 
antibody in a 1/50 dilution was incubated for 32 minutes. 
The primary antibody was visualized using the Ventana 
ultraView Universal Alkaline Phosphatase Red Detection 
Kit (Cat#760-501) for double stain. The single staining of 
PD-1 was performed with same antigen retrieval procedure 
and was visualized with ultraView DAB detection kit.
To visualize the nuclei, all slides were 
counterstained with Ventana Hematoxylin II reagent (Cat# 
790-2208) for 32 minutes, followed by a Bluing reagent 
(Cat# 760-2037) for 8 minutes, and then dehydrated, 
cleared and mounted on glass slides. All double stained 
sections were compared with the corresponding single 
stained slide. Two different controls were applied. First, 
control staining with an isotype-matched control antibody 
without the primary antibody, under the same staining 
protocol as for the primary antibody. Rabbit and mouse 
isotype-matched negative control antibodies were obtained 
from Abcam (PD-L1, Cat#ab27478; PD-1, Cat#ab18443). 
Second, multiple organ TMA as positive and negative 
tissue controls were used to verify the specificity of the 
staining in every staining procedure. The positive tissue 
controls comprised placenta for PD-L1 and tonsil for 
PD-1 (Figure 1). Negative tissue controls were samples of 
normal brain and ventricle for both PD1 and PD-L1.
To confirm staining homogeneity of PD-L1 
throughout the tumor epithelium, we selected six patients 
from TMA slides with different tumoral expression (low, 
moderate, high). Whole tissue sections of these patients 
were further stained with PD-L1 (Cat#13684, clone: 
E1L3N), and analyzed by an experienced pathologist who 
approved staining homogeneity (Supplementary Figure 2). 
Scoring of immunohistochemistry
All tissue samples were scored semi-quantitatively 
by two investigators independent of each other, and 
blinded to clinicopathological data and patient outcome. 
PD-L1 was scored by two experienced pathologists (AV, 
CN) and PD-1 was scored by one experienced pathologist 
(ER) and one trained MD (NN). For each tissue core the 
most experienced pathologist histologically assured the 
tissue type, and if possible 2 cores of TE, 2 of TS, 1 of 
NE and 1 of NS was scored for each case. Because PD-
L1 was uniformly homogenously expressed in epithelial 
cells, an intensity scoring scale was chosen, and were 
as follows: no staining = 0, weak staining = 1, moderate 
staining = 2, and strong staining = 3. PD-L1+ stromal 
cells and PD-1+ lymphocytes were scored as number of 
positive stained cells per 0.6 mm diameter core as follows: 
0 = 0–3, 1 = 4–10, 2 = 11–15, and 3 = > 15. In case of 
major disagreement (scoring difference > 1), the core 
was re-examined and consensus was reached. For each 
case, the mean score was calculated for each tissue 
compartment, and further dichotomized into low and 
high expression. Cut-off values for dichotomization were 
chosen according to a minimal P-value approach (optimal 
cut-off) while also securing statistically sufficient numbers 
in each group, and high scores were defined as follows: (i) 
≥ 0.54 (mean) for PD-L1+ TS cells (ii) ≥ 1.0 for PD-L1 TE 
cells, and (iii) ≥1.25 for intratumoral PD-1+ lymphocytes. 
Scoring agreement between investigators was excellent 
for both markers. The intra-class correlation coefficient 
(reliability coefficient, r) was 0.93 (CI95% 0.92–0.93, 
p < 0.001) for PD-L1 and 0.96 for PD-1 (CI95% 
0.57–0.96, p < 0.001). Slides with CD8 and PD-1-double 
staining were examined, but not quantified by scoring.
Statistical analysis
All statistical analyses were performed using the 
statistical package IBM SPSS, version 23 (SPSS Inc., 
Chicago, IL). The IHC scoring values from each observer 
were compared for inter-observer reliability by use of a 
two-way random effect model with absolute agreement 
definition. Spearman’s rank-correlation was used to 
examine the associations between PD-L1 and PD-1 
expressions, previously published lymphocyte markers 
[15] and clinicopathological markers. Presented r-values 
are the Spearman's rank correlation coefficient. Univariate 
Cox regression analysis was used to generate HR for 
each individual variable. Univariate survival analyses 
were done by using the Kaplan–Meier method, and the 
difference between survival curves was assessed by the 
log-rank test. The survival curves were terminated at 192 
months, as less than 10% of patients were at risk after 
this point. All significant variables from the univariate 
analyses were assessed in multivariate survival models 
using a backward stepwise Cox regression model with a 
probability for stepwise entry or removal at p = 0.05 and 
0.10, respectively. The significance level was p < 0.05 for 
all analyses. All survival analyses were carried out using 
BF and CF as endpoints. BF was characterized as a PSA 
≥ 0.4 ng/ml, and rising in a minimum of two different 
blood samples postoperatively. BFFS was calculated as 
time from surgery to last follow-up date or the date PSA 
was first measured above threshold. CF was defined as 
verified local, symptomatic cancer recurrence and/or 
radiological verified metastasis to bone, visceral organs 
or lymph nodes after prostatectomy. CFFS was calculated 
from date of surgery to last follow-up date without CF or 
to date of CF. 
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